Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emmessar Biotech & Nutrition filed the outcome of its August 7, 2025 board meeting. The key item is the submission of unaudited financial results for the quarter ended June 30, 2025 (Q1 FY26), reviewed by statutory auditors V Nagarajan & Co. (partner: Shankar Cherekupally). The auditor issued a clean limited review report with no qualifications, confirming the results are prepared in line with Ind AS 34 and SEBI LODR requirements. The 35th Annual General Meeting is scheduled for Friday, September 26, 2025, to be held via video conferencing in compliance with MCA/SEBI circulars. Remote e-voting will run from September 23 to September 25, 2025, with the cut-off date set as September 19, 2025. Specific revenue, PAT, and segment-level figures in the attachment were not legible in the source document.
Routine quarterly disclosure with an unmodified auditor's review – no red flags on audit quality, governance, or going-concern. No material new information for shareholders beyond standard results filing and AGM logistics.